Page last updated: 2024-12-07

1-(carboxymethylthio)tetradecane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

The compound you're asking about, **1-(carboxymethylthio)tetradecane**, is not a commonly known or researched chemical. It's possible there's a typo or it's a very niche compound.

However, let's break down the components of the name and explore potential reasons for its importance:

* **1-(carboxymethylthio)**: This indicates a functional group consisting of a carboxylic acid (-COOH) attached to a sulfur atom (-S-) which is further linked to a methylene group (-CH2-).
* **tetradecane**: This refers to a straight-chain alkane with 14 carbon atoms (C14H30).

Based on this structure, the compound likely has:

* **Surfactant properties**: The long hydrocarbon chain (tetradecane) could make it hydrophobic, while the carboxyl group could contribute to hydrophilic behavior. This combination is typical of surfactants, which have diverse applications in cleaning, cosmetics, and other industries.
* **Potential biological activity**: The sulfur-containing functional group could interact with biological molecules. This could lead to potential applications in medicine, agriculture, or other areas.

**To determine the specific importance of this compound for research, we would need more information:**

* **Where did you encounter this name?** Is it from a research paper, a chemical database, or elsewhere?
* **What context was it presented in?** Was it mentioned in relation to a particular application or biological process?

With more context, it might be possible to identify the specific reasons for its research significance.

**Without more information, it's difficult to say definitively why 1-(carboxymethylthio)tetradecane is important. However, its structure suggests it could be a potentially interesting molecule with surfactant or biological properties.**

1-(carboxymethylthio)tetradecane: structure given in first source; alkylthio acetic acid, non-beta-oxidizable [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114924
CHEMBL ID187734
CHEBI ID94633
SCHEMBL ID207756
MeSH IDM0171961

Synonyms (58)

Synonym
EU-0101155
tetradecylthioacetic acid, >=97% (nmr)
NCGC00016005-01
lopac-t-1698
LOPAC0_001155
SPECTRUM5_001951
NCGC00094417-04
NCGC00094417-03
1-(carboxymethylthio)tetradecane
acetic acid, (tetradecylthio)-
1-mono(carboxymethylthio)tetradecane
tetradecylthioacetic acid
cmtd
NCGC00094417-02
NCGC00094417-01
NCGC00016005-02
T 1698
NCGC00016005-06
tetradecylsulfanyl-acetic acid
CHEMBL187734
AKOS005067132
2921-20-2
2-tetradecylsulfanylacetic acid
HMS3263H11
2-(tetradecylthio)acetic acid
A819812
CCG-205229
7zu5i25s2o ,
unii-7zu5i25s2o
NCGC00016005-04
NCGC00016005-05
NCGC00016005-03
FT-0634553
LP01155
BRD-K47539947-001-01-1
SCHEMBL207756
IPBCWPPBAWQYOO-UHFFFAOYSA-N
acetic acid, 2-(tetradecylthio)-
T3787
tox21_501155
NCGC00261840-01
Q-201808
DTXSID0040759
CHEBI:94633
SR-01000076149-4
sr-01000076149
SR-01000076149-1
mfcd00128230
Q7706312
SDCCGSBI-0051122.P002
NCGC00016005-08
tetradecylthioacetic-acid
D92744
2-tetradecylsulfanylethanoic acid
t4t ,
2-(tetradecylthio)aceticacid
BS-42183
HY-139040

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety was evaluated by following the adverse events, vital signs, and hematological and biochemical parameters in blood and urine samples."( Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study.
Berge, RK; Nordrehaug, JE; Pettersen, RJ; Salem, M; Skorve, J; Ulvik, RJ, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
straight-chain fatty acidAny fatty acid whose skeletal carbon atoms form an unbranched open chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency18.31740.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency18.31740.025120.237639.8107AID886; AID893
Chain A, Ferritin light chainEquus caballus (horse)Potency19.95265.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency19.95260.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency23.77810.100020.879379.4328AID588453; AID588456
USP1 protein, partialHomo sapiens (human)Potency25.11890.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency26.96800.180013.557439.8107AID1460
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency50.11870.000214.376460.0339AID588532
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency47.39350.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency28.18380.001019.414170.9645AID588536
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency15.84890.023723.228263.5986AID588543
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.08910.540617.639296.1227AID2364; AID2528
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency19.95260.316212.443531.6228AID902
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency12.58930.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency79.43280.010039.53711,122.0200AID1469
DNA polymerase betaHomo sapiens (human)Potency31.62280.022421.010289.1251AID485314
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency36.47350.000627.21521,122.0200AID651741; AID720636
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency23.93410.425612.059128.1838AID504536
gemininHomo sapiens (human)Potency15.84890.004611.374133.4983AID463097
M-phase phosphoprotein 8Homo sapiens (human)Potency31.62280.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency10.00000.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.12590.00106.000935.4813AID943
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Alpha-synucleinHomo sapiens (human)Potency29.09290.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency36.53550.00638.235039.8107AID881; AID883
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency10.00000.015823.527344.6684AID651778
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (145)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (51)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (88)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID346115Effect on fatty acid composition in Wistar rat assessed as change in plasma MUFA level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278964Effect on fatty acid composition in human myotubes assessed as intracellular dTTA level at 30 uM after 96 hrs2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346124Effect on fatty acid composition in Wistar rat assessed as change in liver 18;2, n-6 level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID476933Activation of PPARdelta expressed in human MCF7 cells at 30 uM by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPAR alpha selective.
AID346120Drug level in Wistar rat liver at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278967Effect on fatty acid composition in human myotubes assessed as intracellular MUFA level at 30 uM after 96 hrs (Rvb= 41.04%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346133Effect on fatty acid composition in Wistar rat assessed as change in liver LCn-6/18:2 level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278970Effect on fatty acid composition in human myotubes assessed as intracellular PUFA n-9 level at 30 uM after 96 hrs (Rvb= 1.78%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278956Effect on fatty acid composition in human myotubes assessed as intracellular dTTA level at 10 uM after 96 hrs2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346102Induction of PPAR-alpha-regulated CPT2 activity in po dosed Wistar rat after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278961Effect on fatty acid composition in human myotubes assessed as intracellular PUFA n-6 level at 10 uM after 96 hrs (Rvb= 13.41%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278987Induction of fatty acid oxidation in human myotubes using [14C]oleic acid as substrate at 30 uM preincubated for 96 hrs followed by substrate addition incubated for 4 hrs by liquid scintillation analysis relative to control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346131Effect on fatty acid composition in Wistar rat assessed as change in liver 18;2, n-6 level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID476931Activation of PPARalpha expressed in human MCF7 cells at 30 uM by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPAR alpha selective.
AID1278955Effect on fatty acid composition in human myotubes assessed as intracellular TTA level at 10 uM after 96 hrs2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346123Effect on fatty acid composition in Wistar rat assessed as change in liver PUFA level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346104Increase in [1-14C]palmitoyl-CoA oxidation in po dosed Wistar rat liver homogenate after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278984Effect on fatty acid composition in human myotubes assessed as change in intracellular MUFA level at 30 uM after 96 hrs relative to DMSO control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346126Effect on fatty acid composition in Wistar rat assessed as change in liver LCn-6/18:2 level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346132Effect on fatty acid composition in Wistar rat assessed as change in liver LCPUFA, n-6 level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346113Plasma concentration in Wistar rat at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278969Effect on fatty acid composition in human myotubes assessed as intracellular PUFA n-6 level at 30 uM after 96 hrs (Rvb= 13.41%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346128Effect on fatty acid composition in Wistar rat assessed as change in liver saturated fatty acid level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278959Effect on fatty acid composition in human myotubes assessed as intracellular MUFA level at 10 uM after 96 hrs (Rvb= 41.04%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346116Effect on fatty acid composition in Wistar rat assessed as change in plasma PUFA level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346092Decrease in plasma cholesterol level in po dosed Wistar rat after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278991Agonist activity at PPAR in human myotubes assessed as CPT1A mRNA expression at 30 uM after 96 hrs by qPCR analysis relative to control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346099Induction of PPAR-alpha-regulated fatty acyl-CoA oxidase activity in po dosed Wistar rat after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278966Effect on fatty acid composition in human myotubes assessed as intracellular SFA level at 30 uM after 96 hrs (Rvb= 36.16%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278983Effect on fatty acid composition in human myotubes assessed as change in intracellular MUFA level at 10 uM after 96 hrs relative to DMSO control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346109Effect on fatty acid composition in Wistar rat assessed as change in plasma PUFA level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278990Agonist activity at PPAR in human myotubes assessed as CD36 mRNA expression at 30 uM after 96 hrs by qPCR analysis relative to control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346093Decrease in plasma triacylglycerol level in po dosed Wistar rat after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346119Effect on fatty acid composition in Wistar rat assessed as change in plasma LCn-6/18:2 level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278982Effect on fatty acid composition in human myotubes assessed as change in intracellular SFA level at 30 uM after 96 hrs relative to DMSO control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID346111Effect on fatty acid composition in Wistar rat assessed as change in plasma LCPUFA, n-6 level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278968Effect on fatty acid composition in human myotubes assessed as intracellular PUFA n-3 level at 30 uM after 96 hrs (Rvb= 7.47%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278989Agonist activity at PPAR in human myotubes assessed as FABP3 mRNA expression at 30 uM after 96 hrs by qPCR analysis relative to control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346114Effect on fatty acid composition in Wistar rat assessed as change in plasma saturated fatty acid level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID248137Concentration required for inhibition of lipid synthesis in primary cultures of rat hepatocytes2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.
AID346129Effect on fatty acid composition in Wistar rat assessed as change in liver MUFA level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346098Induction of PPAR-alpha-regulated HMG-CoA synthase activity in po dosed Wistar rat after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278988Agonist activity at PPAR in human myotubes assessed as ANGPTL4 mRNA expression at 30 uM after 96 hrs by qPCR analysis relative to control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346125Effect on fatty acid composition in Wistar rat assessed as change in liver LCPUFA, n-6 level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278986Effect on intracellular [14C]oleic acid uptake in human myotubes at 10 to 30 uM preincubated for 96 hrs followed by substrate addition incubated for 4 hrs by liquid scintillation analysis2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346110Effect on fatty acid composition in Wistar rat assessed as change in plasma 18;2, n-6 level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346130Effect on fatty acid composition in Wistar rat assessed as change in liver PUFA level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346107Effect on fatty acid composition in Wistar rat assessed as change in plasma saturated fatty acid level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278992Effect on protein level in human myotubes at 10 to 30 uM2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346112Effect on fatty acid composition in Wistar rat assessed as change in plasma LCn-6/18:2 level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346117Effect on fatty acid composition in Wistar rat assessed as change in plasma 18;2, n-6 level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346122Effect on fatty acid composition in Wistar rat assessed as change in liver MUFA level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278993Effect on total fatty acid level in human myotubes assessed as per mg of protein at 10 to 30 uM2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278985Induction of fatty acid oxidation in human myotubes using [14C]oleic acid as substrate preincubated for 96 hrs followed by substrate addition incubated for 4 hrs by liquid scintillation analysis2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278958Effect on fatty acid composition in human myotubes assessed as intracellular SFA level at 10 uM after 96 hrs (Rvb= 36.16%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346121Effect on fatty acid composition in Wistar rat assessed as change in liver saturated fatty acid level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346108Effect on fatty acid composition in Wistar rat assessed as change in plasma MUFA level at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID346118Effect on fatty acid composition in Wistar rat assessed as change in plasma LCPUFA, n-6 level at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID476935Activation of PPARgamma expressed in human MCF7 cells at 30 uM by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPAR alpha selective.
AID346106Plasma concentration in Wistar rat at 85 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1278963Effect on fatty acid composition in human myotubes assessed as intracellular TTA level at 30 uM after 96 hrs2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278962Effect on fatty acid composition in human myotubes assessed as intracellular PUFA n-9 level at 10 uM after 96 hrs (Rvb= 1.78%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278960Effect on fatty acid composition in human myotubes assessed as intracellular PUFA n-3 level at 10 uM after 96 hrs (Rvb= 7.47%)2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID1278981Effect on fatty acid composition in human myotubes assessed as change in intracellular SFA level at 10 uM after 96 hrs relative to DMSO control2016Bioorganic & medicinal chemistry, Mar-15, Volume: 24, Issue:6
The molecular structure of thio-ether fatty acids influences PPAR-dependent regulation of lipid metabolism.
AID346127Drug level in Wistar rat liver at 250 uM, po after 6 days2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Synthesis and analysis of novel glycerolipids for the treatment of metabolic syndrome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (143)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.70)18.7374
1990's51 (35.66)18.2507
2000's53 (37.06)29.6817
2010's31 (21.68)24.3611
2020's7 (4.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.81 (24.57)
Research Supply Index5.00 (2.92)
Research Growth Index6.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (3.50%)5.53%
Reviews2 (1.40%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other136 (95.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
TTA in Treatment of Diabetes and Dyslipidemia [NCT00605787]Phase 216 participants (Actual)Interventional2002-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]